Panteli Theocharous | Chief Executive Officer; Chair of the Board, The Malcom Orlando Ivy Foundation (TMOIF)
VectorGen

Dr. Panteli Theocharous, PhD, FRCPath, is a globally recognised biotech executive and translational scientist with more than 35-years of leadership across haematology/oncology, cell and gene therapy, and advanced therapeutics. Trained as a clinical immunologist at the Royal Free Hospital and UCL, he is a pioneer in stem cell transplantation, and minimal residual disease detection, with foundational scientific contributions adopted into international diagnostic and translational standards. He has held executive C-suite and global leadership roles across biotech, biopharma, and CRO environments, including Chief Therapeutics Officer, Chief Medical Officer, and Worldwide Head of Cell & Gene Therapy Strategy at Thermo Fisher Scientific/PPD. In these roles, Dr. Theocharous has led complex programmes from preclinical development through regulatory approval and commercialisation, engaging extensively with FDA, EMA, and global HTA bodies. His career reflects consistent enterprise value creation, contributing to significant transaction and partnership value, and supporting multiple successful venture financings, including a recent $55M Series A-1 financing round. He is currently Chief Executive Officer of VectorGen, advancing next-generation lentiviral vector platforms for precision and potentially curative therapies, and serves as Chair of the Board of The Malcolm Orlando Ivy Foundation, reinforcing his commitment to patient-centric innovation and access. A frequent invited speaker across the CGT ecosystem, he contributes thought leadership on clinical strategy, supply chain resilience, and patient journey design. He currently serves in executive, board, and advisory roles across innovative cell and gene therapy ventures, where he is valued as a strategic operator, trusted advisor, and builder of durable, high-impact organisations.